Fibrosis frontal attack

Pliant Therapeutics Inc. was formed to develop fibrosis products based on collaborative work by UCSF biologists and chemists that identified the primary culprit of TGF beta activation, along with small molecules that can inhibit that activation. The company expects its compounds to halt or reverse a range of fibrotic conditions.

Pliant is starting with idiopathic pulmonary fibrosis, where treatments slow but do not stop progression...